GIANT BIOGENE HOLDING CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.9 HKD | +1.98% |
|
+1.88% | +37.08% |
| Apr. 30 | Giant Biogene’s Profit Up 47% in 2023 | MT |
| Mar. 26 | Giant Biogene to Pay Special 0.45 Yuan per Share Dividend | MT |
| Sales 2024 * | 4.67B 646M 5.05B | Sales 2025 * | 5.99B 827M 6.47B | Capitalization | 43.31B 5.98B 46.77B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.8B 248M 1.94B | Net income 2025 * | 2.28B 314M 2.46B | EV / Sales 2024 * | 8.4 x |
| Net cash position 2024 * | 4.03B 556M 4.35B | Net cash position 2025 * | 5.46B 754M 5.9B | EV / Sales 2025 * | 6.32 x |
| P/E ratio 2024 * |
24.4
x | P/E ratio 2025 * |
19.3
x | Employees | 1,164 |
| Yield 2024 * |
1.18% | Yield 2025 * |
1.5% | Free-Float | 40.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.77% | ||
| 1 week | +1.88% | ||
| Current month | +14.69% | ||
| 1 month | +11.29% | ||
| 3 months | +49.01% | ||
| 6 months | +55.66% | ||
| Current year | +37.08% |
1 week
44.95
49.15
1 month
41.4549.15
Current year
28.7549.15
1 year
28.4049.15
3 years
24.3058.80
5 years
24.3058.80
10 years
24.3058.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Ya Yan
CEO | Chief Executive Officer | 58 | 00-04-30 |
Hui Juan Zhang
DFI | Director of Finance/CFO | 37 | - |
Yu Bo Yan
BRD | Director/Board Member | 28 | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sze Wing Wong
BRD | Director/Board Member | 46 | 22-04-20 |
Jian Ya Yan
CEO | Chief Executive Officer | 58 | 00-04-30 |
Juan Ye
BRD | Director/Board Member | 53 | 21-11-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-01 | 48.9 | +1.98% | 673 872 |
| 24-04-30 | 47.95 | +3.79% | 3,281,954 |
| 24-04-29 | 46.2 | -3.85% | 5,725,209 |
| 24-04-26 | 48.05 | +0.73% | 1,935,432 |
| 24-04-25 | 47.7 | -0.62% | 2,090,904 |
Delayed Quote Hong Kong S.E., May 01, 2024 at 11:50 pm EDT
More quotes
Giant Biogene Holding Co Ltd is a China-based investment holding company. The Company is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The Company's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The Company also develops and manufactures rare ginsenosides technology-based functional foods. The Company mainly conducts its businesses within the domestic market.
Sector
Personal Products
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
47.95
HKD
Average target price
53.88
HKD
Spread / Average Target
+12.37%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.08% | 5.98B | |
| +11.51% | 385B | |
| +8.95% | 130B | |
| +15.29% | 75.41B | |
| -15.91% | 62.79B | |
| -12.91% | 52.59B | |
| -12.45% | 36.03B | |
| +3.57% | 33.64B | |
| +9.84% | 17.55B | |
| +9.74% | 14.94B |
- Stock Market
- Equities
- 2367 Stock
